How long Invega (paliperidone) stays in your system depends entirely on which formulation you take. The oral tablet clears in roughly 5 to 6 days after your last dose. The monthly injection can linger for several months. And the longest-acting injectable version can remain detectable in your body for well over a year after a single shot.
These differences are dramatic, and they matter if you’re switching medications, experiencing side effects, or planning to stop treatment. Here’s what to expect for each formulation.
Oral Invega Tablets
The extended-release tablet has a half-life of approximately 23 hours. That means roughly half the drug is eliminated from your body every day. After about five half-lives, a drug is generally considered cleared from your system, which puts the timeline for oral Invega at around 5 to 6 days after your last pill.
Steady-state concentrations (the point where intake and elimination are balanced) build up within 4 to 5 days of daily dosing. So the drug reaches its full working level quickly and leaves relatively quickly once you stop.
Monthly Injection (Invega Sustenna)
The monthly injectable version works very differently. It uses a slow-release formulation injected into muscle tissue, where it gradually dissolves and enters the bloodstream over weeks. The median half-life ranges from 25 to 49 days depending on the dose, and the drug release from a single injection can last up to 126 days (about 4 months).
Using the five half-life rule, a single Sustenna injection could take anywhere from 4 to 8 months to fully clear your system. If you’ve been receiving regular monthly injections and then stop, the timeline starts from your last shot, but prior doses are still releasing and overlapping. Realistically, you should expect the drug to remain in your body for many months after your final injection.
This extended presence is one of the key reasons doctors prescribe the injectable form: it keeps working even if you miss an appointment. But it also means side effects can persist long after you decide to stop.
3-Month Injection (Invega Trinza)
Invega Trinza is designed for patients already stabilized on the monthly injection who want fewer appointments. It has a considerably longer half-life: 84 to 95 days when injected into the deltoid (shoulder) and 118 to 139 days when injected into the gluteal muscle (buttock).
Five half-lives from the gluteal injection puts total clearance at roughly 590 to 695 days, or nearly two years. Even from a deltoid injection, you’re looking at 14 to 16 months. The injection site matters because the drug absorbs at different rates depending on the surrounding tissue.
6-Month Injection (Invega Hafyera)
The longest-acting formulation has a median half-life of 148 to 159 days, depending on the dose. That translates to a potential clearance window of roughly 2 to 2.5 years after a single injection. This is the slowest-clearing antipsychotic formulation available.
If you experience a serious side effect on Hafyera, there is no way to speed up elimination. The drug is embedded in muscle tissue and releases on its own schedule. This is an important consideration before choosing this formulation.
Why the Injectables Last So Long
The active ingredient is the same across all four formulations. The difference is delivery. The oral tablet dissolves in your gut and enters the bloodstream within hours. The injectables use a salt form of paliperidone (paliperidone palmitate) that forms a depot, essentially a small reservoir, in the muscle at the injection site. The drug slowly converts to its active form and seeps into the bloodstream over weeks or months.
The half-life listed for each injectable is actually controlled by absorption speed, not by how fast your liver processes the drug. Your body can break down paliperidone relatively quickly once it hits the bloodstream. The bottleneck is how slowly the depot releases it. This is why the same molecule can have a 23-hour half-life as a pill and a 159-day half-life as a 6-month injection.
Kidney Function Changes the Timeline
Your kidneys play a major role in clearing paliperidone. The drug is processed to some extent by liver enzymes, but renal excretion is the primary route out of the body. If your kidneys aren’t working at full capacity, the drug stays in your system significantly longer.
In people with mild kidney impairment, total clearance drops by about 32%, and drug exposure increases roughly 1.5 times compared to someone with normal kidney function. Moderate impairment reduces clearance by 64%, increasing exposure 2.6-fold. Severe impairment cuts clearance by 71%, leading to nearly 5 times the drug exposure. The oral tablet’s half-life rises from 23 hours in healthy kidneys to about 40 hours with moderate impairment and 51 hours with severe impairment.
For the injectable formulations, reduced kidney function compounds an already long elimination timeline. A published case report highlighted the risk of serious toxicity when long-acting paliperidone was given to a patient with chronic kidney disease, because the drug accumulated far beyond expected levels.
Summary by Formulation
- Oral tablets: Half-life of ~23 hours. Expect clearance in about 5 to 6 days.
- Monthly injection (Sustenna): Half-life of 25 to 49 days. Expect clearance in roughly 4 to 8 months.
- 3-month injection (Trinza): Half-life of 84 to 139 days depending on injection site. Expect clearance in roughly 14 months to 2 years.
- 6-month injection (Hafyera): Half-life of 148 to 159 days. Expect clearance in roughly 2 to 2.5 years.
These timelines assume normal kidney function. Reduced kidney function, higher doses, and longer treatment histories can all extend these windows. If you’re concerned about how long the drug will remain active in your body, the formulation you’re on is by far the most important variable.